A Phase 3 interventional study of Garetosmab and Placebo in Fibrodysplasia Ossificans Progressiva, sponsored by Regeneron Pharmaceuticals. Active, not recruiting at 22 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Regeneron Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study is researching an experimental drug called garetosmab. The study is focused on adult patients with fibrodysplasia ossificans progressiva (FOP).
The aim of the study is to see how safe and effective the study drug is in patients with FOP.
The study is looking at several other research questions, including:
24 studies on the registry are indexed under Myositis Ossificans; 5 are open to participants now.
This study's enrollment of 63 is above the median of 48 across 16 interventional studies indexed under Myositis Ossificans.
Browse Myositis Ossificans studies →Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.
Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
History of poorly controlled hypertension, as defined by:
Note: Other protocol defined Inclusion/Exclusion Criteria apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Garetosmab is administered by intravenous (IV) administration every 4 weeks (Q4W)
Drug: Garetosmab
Garetosmab is administered by IV administration Q4W
Drug: Garetosmab
Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV Q4W.
Drug: Placebo
Garetosmab is supplied as a liquid drug product and will be administered IV.
Also known as: REGN2477, PASATRU™
Placebo to match garetosmab, is supplied as a liquid solution without the monoclonal antibody (or the protein) and is administered IV.
Number of New Heterotopic Ossification (HO) Lesions
The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by computed tomography (CT) that developed after baseline. This endpoint represents the cumulative number of New HO Lesions across all participants.
Time frame: Week 56
Number of Participants With Treatment-emergent (TE) Adverse Events of Special Interest (AESIs)
The following were considered AESIs: * Epididymitis, orchitis, hydrocele, scrotum pain and/or scrotum swelling * Moderate-to-severe episodes of spontaneous non-traumatic bleeding * Moderate epistaxis * Severe epistaxis * Skin infection/abscess that requires referral to specialist for treatment
Time frame: Baseline up to Week 56 [to include participants who discontinued earlier]
Number of Clinician-assessed Flare-ups
Investigator assessed flare-up events according to his/her medical judgment. A FOP flare-up was characterized as episodic, painful inflammatory soft tissue swelling. This endpoint represents the cumulative number of Clinician-assessed Flare-ups across all participants.
Time frame: Baseline through Weeks 28 and 56
Number of Participants With New HO Lesions at Weeks 28 and 56
Reported as Yes/No The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.
Time frame: Weeks 28 and 56
Total Volume of New HO Lesions
The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.
Time frame: Weeks 28 and 56
Percentage of Participants With Participant-reported Flare-ups
Reported as Yes/No
Time frame: Baseline through Weeks 28 and 56
Number of New HO Lesions
The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.
Time frame: Week 28
Percentage of Participants With Clinician-assessed Flare-ups
Reported as Yes/No
Time frame: Baseline through Weeks 28 and 56
Number of Participant-reported Flare-ups
Flare-up is defined as two or more of the following: pain, swelling, joint stiffness, or decrease in movement. The FOP flare-up dairy is a questionnaire and is self-completed by the participant daily. This endpoint represents the cumulative number of Participant-reported Flare-ups across all participants.
Time frame: Baseline through Weeks 28 and 56
Change From Baseline in Joint Function Assessment by Physician Using Cumulative Analog Joint Involvement Scale (CAJIS)
CAJIS is a clinician assessment of 15 major joints; each major joint rated normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30
Time frame: Baseline, Weeks 28 and 56
Change in Pulmonary Function (Forced Expiratory Volume in 1 Second [FEV1]) as Assessed by Spirometry
Forced expiratory volume in 1 second (FEV1) will be determined by spirometry.
Time frame: Baseline, Weeks 28 and 56
Change From Baseline in Disease Severity as Assessed by the Patient Global Impression of Severity (PGIS)
PGIS is a single item, self-administered questionnaire to assess the participant's global impression of severity. PGIS scores range from 0 to 4 (\[0\]: none, \[1\]: mild, \[2\]: moderate, \[3\]: severe, \[4\]: very severe). LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect and the baseline value as continuous covariate
Time frame: Baseline, Weeks 28 and 56
Patient's Global Impression of Change (PGIC) Scale Score
PGIC is a single item, self-administered questionnaire to assess the patient's global impression of change. The PGIC scale uses a 7-point rating format where participants select the response that best describes how their condition has changed: 1 = Very much improved, 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect.
Time frame: Weeks 28 and 56
Clinician's Global Impression of Change (CGIC) Scale Score
CGIC is a single-item questionnaire to assess the clinician's global impression of change. The clinician assessed the participant's condition and scored the change using the following standard 7-point scale: 1 = Very much improved, 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect.
Time frame: At Weeks 28 and 56
Concentration of Total Activin A in Serum Over Time
Concentrations below the lower limit of quantitation (LLOQ) (0.000313 milligrams \[mg\]/L) were set to 0.
Time frame: Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
Concentration of Garetosmab in Serum Over Time
Concentrations below the LLOQ (0.078 mg/L) were set to 0.
Time frame: Day 1 (Week 0) predose and 30 minutes after the end of infusion (nominal Week 0.003), and Weeks 1, 4, 8, 12, 16, 20, 28, 36, 40, 44, 48, 52 and 56
Number of Participants With Anti-drug Antibodies (ADA) to Garetosmab Over Time
Time frame: Baseline through Week 56
Number of Participants With Titer Values of ADA to Garetosmab Over Time Through Week 56
Time frame: Baseline through Week 56
Number of Clinician-assessed Flare-ups at Week 84
Investigator assessed flare-up events according to his/her medical judgment. A FOP flare-up was characterized as episodic, painful inflammatory soft tissue swelling. Week 84 Only for Patients on Extended Treatment
Time frame: Through Week 84
Percentage of Participants With New HO Lesions at Week 84
Reported as Yes/No Week 84 Only for Patients on Extended Treatment
Time frame: At Week 84
Total Volume of New HO Lesions
Week 84 Only for Patients on Extended Treatment
Time frame: At Week 84
Number of New HO Lesions
Week 84 Only for Participants on Extended Treatment
Time frame: At week 84
Percentage of Participants With Clinician-assessed Flare-ups
Reported as Yes/No Week 84 Only for Participants on Extended Treatment
Time frame: Through Week 84
Change in Pulmonary Function (Forced Vital Capacity (FVC)) as Assessed by Spirometry
FVC will be determined by spirometry.
Time frame: Baseline, Weeks 28 and 56
Change in Pulmonary Function (FEV1/FVC) as Assessed by Spirometry
The ratio of FEV1/FVC will be determined by spirometry.
Time frame: Baseline, Weeks 28 and 56
| Milestone | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Started | 19 | 23 | 21 |
| Completed | 19 | 23 | 20 |
| Not completed | 0 | 0 | 1 |
| Withdrew: Adverse event | 0 | 0 | 1 |
| Milestone | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Started | 19 | 22 | 20 |
| Completed | 19 | 22 | 20 |
| Not completed | 0 | 0 | 0 |
The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by computed tomography (CT) that developed after baseline. This endpoint represents the cumulative number of New HO Lesions across all participants.
| Lesions | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Number of New Heterotopic Ossification (HO) Lesions | 1 | 2 | 19 |
The following were considered AESIs: * Epididymitis, orchitis, hydrocele, scrotum pain and/or scrotum swelling * Moderate-to-severe episodes of spontaneous non-traumatic bleeding * Moderate epistaxis * Severe epistaxis * Skin infection/abscess that requires referral to specialist for treatment
| Participants | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| TE-AESI | 0 | 4 | 1 |
| Severe TE-AESI | 0 | 0 | 0 |
| TE serious AESI | 0 | 1 | 0 |
| Treatment-related TE-AESI | 0 | 4 | 1 |
| TE-AESI leading to study treatment discontinuation | 0 | 0 | 0 |
| TE-AESI leading to death | 0 | 0 | 0 |
Investigator assessed flare-up events according to his/her medical judgment. A FOP flare-up was characterized as episodic, painful inflammatory soft tissue swelling. This endpoint represents the cumulative number of Clinician-assessed Flare-ups across all participants.
| Flare-ups | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Week 28 | 38 | 5 | 42 |
| Week 56 | 53 | 9 | 66 |
Reported as Yes/No The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.
| Participants | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Week 28 | 1 | 1 | 3 |
| Week 56 | 1 | 2 | 5 |
The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.
| cubic centimeters (cm^3) | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Week 28 | 0.01 ± 0.06 | 0.01 ± 0.04 | 6.02 ± 22.81 |
| Week 56 | 0.01 ± 0.04 | 0.02 ± 0.06 | 10.97 ± 37.37 |
Reported as Yes/No
| Percentage of participants | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Week 28 | 57.9 | 43.5 | 47.6 |
| Week 56 | 57.9 | 47.8 | 61.9 |
The HO is the abnormal growth of bone in non-skeletal tissues. New HO lesions were defined as HO lesions detectable by CT that developed after baseline.
| Lesions | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Number of New HO Lesions | 1 | 1 | 11 |
Reported as Yes/No
| Percentage of participants | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Week 28 | 42.1 | 13.0 | 42.9 |
| Week 56 | 42.1 | 21.7 | 71.4 |
Flare-up is defined as two or more of the following: pain, swelling, joint stiffness, or decrease in movement. The FOP flare-up dairy is a questionnaire and is self-completed by the participant daily. This endpoint represents the cumulative number of Participant-reported Flare-ups across all participants.
| Flare-ups | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Week 28 | 68 | 67 | 65 |
| Week 56 | 86 | 109 | 100 |
CAJIS is a clinician assessment of 15 major joints; each major joint rated normal unaffected (0), affected (1), or completely functionally ankylosed (2). The total score ranges from 0 to 30
| Score on a scale | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Change at Week 28 | -0.4 ± 0.47 | -0.2 ± 0.42 | -0.3 ± 0.45 |
| Change at Week 56 | -0.1 ± 0.51 | 0.0 ± 0.45 | -0.4 ± 0.48 |
Forced expiratory volume in 1 second (FEV1) will be determined by spirometry.
| Liters (L) | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Week 28 | -0.2702 ± 0.21907 | 0.0709 ± 0.23015 | -0.0019 ± 0.20468 |
| Week 56 | -0.1237 ± 0.16475 | -0.5196 ± 0.17173 | -0.1384 ± 0.16561 |
PGIS is a single item, self-administered questionnaire to assess the participant's global impression of severity. PGIS scores range from 0 to 4 (\[0\]: none, \[1\]: mild, \[2\]: moderate, \[3\]: severe, \[4\]: very severe). LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect and the baseline value as continuous covariate
| Score on a scale | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Change at Week 28 | -0.5 ± 0.17 | -0.7 ± 0.15 | -0.7 ± 0.16 |
| Change at Week 56 | -0.4 ± 0.18 | -0.7 ± 0.16 | -0.5 ± 0.17 |
PGIC is a single item, self-administered questionnaire to assess the patient's global impression of change. The PGIC scale uses a 7-point rating format where participants select the response that best describes how their condition has changed: 1 = Very much improved, 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect.
| Score on a scale | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Week 28 | 2.7 ± 0.23 | 2.8 ± 0.21 | 3.2 ± 0.23 |
| Week 56 | 2.7 ± 0.27 | 2.6 ± 0.24 | 3.1 ± 0.26 |
CGIC is a single-item questionnaire to assess the clinician's global impression of change. The clinician assessed the participant's condition and scored the change using the following standard 7-point scale: 1 = Very much improved, 2 = Much improved; 3 = Minimally improved; 4 = No change; 5 = Minimally worse; 6 = Much worse; 7 = Very much worse. LS mean and SE were calculated using ANCOVA model, which included treatment as fixed effect.
| Scores on a scale | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Week 28 | 2.8 ± 0.23 | 3.1 ± 0.22 | 3.3 ± 0.22 |
| Week 56 | 2.7 ± 0.24 | 2.9 ± 0.22 | 3.1 ± 0.23 |
Concentrations below the lower limit of quantitation (LLOQ) (0.000313 milligrams \[mg\]/L) were set to 0.
| milligrams per Liter (mg/L) | Placebo | Low Dose Garetosmab | High Dose Garetosmab |
|---|---|---|---|
| Day 1 (Week 0) predose | 0.000114 ± 0.000313 | 0.000150 ± 0.000358 | 0.000110 ± 0.000301 |
| 30 minutes after the end of infusion (nominal Week 0.003) | 0.000115 ± 0.000349 | 0.000139 ± 0.000449 | 0.000131 ± 0.000424 |
| Week 1 | 0.000141 ± 0.000321 | 0.0184 ± 0.00663 | 0.0240 ± 0.0106 |
| Week 4 | 0.000120 ± 0.000228 | 0.0237 ± 0.0145 | 0.0314 ± 0.0141 |
| Week 8 | 0.000193 ± 0.000448 | 0.0245 ± 0.00822 | 0.0382 ± 0.0175 |
| Week 12 | 0.0000855 ± 0.000180 | 0.0255 ± 0.00794 | 0.0377 ± 0.0159 |
| Week 16 | 0.0000927 ± 0.000203 | 0.0263 ± 0.00977 | 0.0371 ± 0.0130 |
| Week 20 | 0.000153 ± 0.000482 | 0.0298 ± 0.0133 | 0.0391 ± 0.0134 |
| Week 28 | 0.000143 ± 0.000431 | 0.0325 ± 0.0113 | 0.0370 ± 0.0133 |
| Week 36 | 0.000157 ± 0.000556 | 0.0279 ± 0.0103 | 0.0363 ± 0.0108 |
| Week 40 | 0.0000166 ± 0.0000725 | 0.0297 ± 0.0115 | 0.0357 ± 0.0115 |
| Week 44 | 0.0000174 ± 0.0000759 | 0.0280 ± 0.0101 | 0.0364 ± 0.0151 |
| Week 48 | 0.0000428 ± 0.000133 | 0.0261 ± 0.00781 | 0.0370 ± 0.0157 |
| Week 52 | 0.0000442 ± 0.000130 | 0.0274 ± 0.00846 | 0.0349 ± 0.0115 |
| Week 56 | 0 ± 0 | 0.0284 ± 0.0109 | 0.0357 ± 0.0119 |
Concentrations below the LLOQ (0.078 mg/L) were set to 0.
| mg/L | Low Dose Garetosmab | High Dose Garetosmab |
|---|---|---|
| Day 1 (Week 0) predose | 0 ± 0 | 0 ± 0 |
| 30 minutes after the end of infusion (nominal Week 0.003) | 55.2 ± 9.97 | 174 ± 47.6 |
| Week 1 | 27.3 ± 5.11 | 96.1 ± 23.4 |
| Week 4 | 12.4 ± 2.97 | 43.7 ± 13.4 |
| Week 8 | 18.1 ± 6.33 | 71.0 ± 28.7 |
| Week 12 | 22.3 ± 7.28 | 79.9 ± 31.4 |
| Week 16 | 23.3 ± 8.44 | 78.9 ± 30.7 |
| Week 20 | 25.1 ± 9.76 | 93.7 ± 36.0 |
| Week 28 | 24.6 ± 7.54 | 88.3 ± 38.3 |
| Week 36 | 23.5 ± 7.49 | 93.1 ± 39.5 |
| Week 40 | 24.5 ± 8.02 | 128 ± 141 |
| Week 44 | 22.9 ± 8.12 | 94.4 ± 37.1 |
| Week 48 | 23.1 ± 7.78 | 96.7 ± 40.5 |
| Week 52 | 22.2 ± 6.62 | 105 ± 57.0 |
| Week 56 | 23.5 ± 6.75 | 90.4 ± 38.4 |
| Participants | Placebo | Low Dose Garetosmab | High Dose Garetosmab |
|---|---|---|---|
| Treatment-Boosted Response | 0 | 0 | 0 |
| Treatment-Emergent Response | 0 | 0 | 0 |
| Participants | Placebo | Low Dose Garetosmab | High Dose Garetosmab |
|---|---|---|---|
| Low (<1,000) | 0 | 0 | 0 |
| Moderate (1,000 to 10,000) | 0 | 0 | 0 |
| High (>10,000) | 0 | 0 | 0 |
Investigator assessed flare-up events according to his/her medical judgment. A FOP flare-up was characterized as episodic, painful inflammatory soft tissue swelling. Week 84 Only for Patients on Extended Treatment
Results for this outcome have not been posted.
Reported as Yes/No Week 84 Only for Patients on Extended Treatment
Results for this outcome have not been posted.
Week 84 Only for Patients on Extended Treatment
Results for this outcome have not been posted.
Week 84 Only for Participants on Extended Treatment
Results for this outcome have not been posted.
Reported as Yes/No Week 84 Only for Participants on Extended Treatment
Results for this outcome have not been posted.
FVC will be determined by spirometry.
| Liters (L) | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Week 28 | 0.7586 ± 0.38391 | -0.1712 ± 0.45596 | 0.2713 ± 0.37088 |
| Week 56 | 0.0811 ± 0.15013 | -0.1001 ± 0.13166 | 0.1368 ± 0.11480 |
The ratio of FEV1/FVC will be determined by spirometry.
| Liters per Liters (L/L) | Low Dose Garetosmab | High Dose Garetosmab | Placebo |
|---|---|---|---|
| Week 28 | 0.001 ± 0.0161 | -0.031 ± 0.0170 | -0.028 ± 0.0141 |
| Week 56 | 0.025 ± 0.0259 | -0.072 ± 0.0241 | -0.026 ± 0.0206 |
Collected over From the date of signing the Informed Consent Form (ICF) up to Week 56. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Low Dose Garetosmab 3 mg | 0/19 (0%) | 1/19 (5.3%) | 18/19 (94.7%) |
| High Dose Garetosmab 10 mg | 0/23 (0%) | 2/23 (8.7%) | 22/23 (95.7%) |
| Placebo | 0/21 (0%) | 2/21 (9.5%) | 21/21 (100%) |
| Event | Low Dose Garetosmab 3 mg | High Dose Garetosmab 10 mg | Placebo |
|---|---|---|---|
| Dengue feverInfections and infestations | 1/19 | 0/23 | 0/21 |
| PneumoniaInfections and infestations | 1/19 | 0/23 | 0/21 |
| Peritonsillar abscessInfections and infestations | 0/19 | 0/23 | 1/21 |
| Ovarian cystReproductive system and breast disorders | 0/19 | 0/23 | 1/21 |
| AbscessInfections and infestations | 0/19 | 1/23 | 0/21 |
| CellulitisInfections and infestations | 0/19 | 1/23 | 0/21 |
| Event | Low Dose Garetosmab 3 mg | High Dose Garetosmab 10 mg | Placebo |
|---|---|---|---|
| EpistaxisRespiratory, thoracic and mediastinal disorders | 10/19 | 4/23 | 5/21 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 5/19 | 4/23 | 9/21 |
| Pain in extremityMusculoskeletal and connective tissue disorders | 2/19 | 0/23 | 8/21 |
| AcneSkin and subcutaneous tissue disorders | 3/19 | 7/23 | 2/21 |
| Back painMusculoskeletal and connective tissue disorders | 1/19 | 1/23 | 6/21 |
| Fibrodysplasia ossificans progressivaCongenital, familial and genetic disorders | 5/19 | 3/23 | 6/21 |
| RashSkin and subcutaneous tissue disorders | 5/19 | 1/23 | 0/21 |
| NasopharyngitisInfections and infestations | 5/19 | 1/23 | 5/21 |
| MadarosisSkin and subcutaneous tissue disorders | 3/19 | 6/23 | 4/21 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/19 | 0/23 | 5/21 |
| Age, Continuous(Years) | Low Dose Garetosmab | High Dose Garetosmab | Placebo | Total |
|---|---|---|---|---|
| Mean | 24.6 ± 6.0 | 25.7 ± 6.3 | 29.3 ± 7.3 | 26.6 ± 6.8 |
| Sex: Female, Male(Participants) | Low Dose Garetosmab | High Dose Garetosmab | Placebo | Total |
|---|---|---|---|---|
| Female | 12 | 15 | 11 | 38 |
| Male | 7 | 8 | 10 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Low Dose Garetosmab | High Dose Garetosmab | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 2 | 5 | 5 | 12 |
| Not Hispanic or Latino | 15 | 18 | 15 | 48 |
| Unknown or Not Reported | 2 | 0 | 1 | 3 |
| Race/Ethnicity, Customized(Participants) | Low Dose Garetosmab | High Dose Garetosmab | Placebo | Total |
|---|---|---|---|---|
| White | 11 | 18 | 13 | 42 |
| Black or African American | 0 | 1 | 0 | 1 |
| Asian | 8 | 4 | 7 | 19 |
| American Indian / Alaskan Native | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Not Reported | 0 | 0 | 0 | 0 |
| Other | 0 | 0 | 0 | 0 |
| Unknown | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code
Time frame: When Regeneron has: received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry) the legal authority to share the data, and ensured the ability to protect participant privacy
Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
Data sharing details ↗ · vivli.org
Ran from Nov 2022 to primary completion in Jul 2025, 31 months.
Results were first posted in Nov 2026, 1 year 4 months after primary completion. A results delay was requested in Jul 2026.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Garetosmab